Eli Lilly is trading up 8.22% at ARS 36,320.00 as investors rotate into healthcare amid inflation and rate concerns weighing on technology stocks. - The October 15 price advance extends the prior session’s gain, rising from the October 14 close of ARS 34,960.00. - Coverage also cited stronger expectations for Lilly’s metabolic-drug business, but identified no discrete October 15 corporate event driving the move.